Neal Doran1,2, Sarah Dubrava3, Robert M Anthenelli1. 1. Department of Psychiatry, Health Sciences, University of California, San Diego. 2. Mental Health Care Line, Veterans Affairs San Diego Healthcare System. 3. Pfizer, Inc New York, NY.
Abstract
Introduction: Despite effective treatments, relapse to smoking remains a vexing global health problem. One predictor of relapse is depressive symptoms. Medications such as varenicline reduce withdrawal-related symptoms of depression, reducing relapse. This study examined whether varenicline moderated the effect of depressive symptoms on relapse, and whether this varied by region of enrollment. Methods:Adult smokers (n = 525; 37% male) with past or current, stable major depressive disorder recruited from United States (n = 255), and European (n = 270) sites participated in a randomized, double-blind cessation treatment trial including 12 weeks of varenicline or placebo, with 40-week nontreatment follow-up. Results: Longitudinal and binary logistic regressions were used to model the probability of sustained abstinence by end of treatment and point-prevalence abstinence in follow-up. The association between depression symptoms and abstinence was moderated by intervention group at end of treatment, and by region during follow-up: more severe symptoms were associated with end-of-treatment relapse for placebo (odds ratio [OR] = 0.91, p = .003), but not varenicline (OR = 0.99, p = .568). During follow-up, increased symptoms of depression predicted greater likelihood of smoking for European (p = .009) but not US participants. Europeans were more likely to be abstinent for both outcomes (p < .01). Conclusions: These results extend studies demonstrating varenicline is associated with less withdrawal-related depression, and suggest it aids cessation even in smokers with depressive symptoms. Findings also suggest regional differences in the relationship between depressive symptoms and cessation that may be related to differences in prevalence. Implications: This study indicates varenicline may aid cessation partially by reducing withdrawal-related symptoms of depression. It also suggests that the impact of depressive symptoms on cessation varies regionally, and that this variation may be related to differences in smoking prevalence.
RCT Entities:
Introduction: Despite effective treatments, relapse to smoking remains a vexing global health problem. One predictor of relapse is depressive symptoms. Medications such as varenicline reduce withdrawal-related symptoms of depression, reducing relapse. This study examined whether varenicline moderated the effect of depressive symptoms on relapse, and whether this varied by region of enrollment. Methods: Adult smokers (n = 525; 37% male) with past or current, stable major depressive disorder recruited from United States (n = 255), and European (n = 270) sites participated in a randomized, double-blind cessation treatment trial including 12 weeks of varenicline or placebo, with 40-week nontreatment follow-up. Results: Longitudinal and binary logistic regressions were used to model the probability of sustained abstinence by end of treatment and point-prevalence abstinence in follow-up. The association between depression symptoms and abstinence was moderated by intervention group at end of treatment, and by region during follow-up: more severe symptoms were associated with end-of-treatment relapse for placebo (odds ratio [OR] = 0.91, p = .003), but not varenicline (OR = 0.99, p = .568). During follow-up, increased symptoms of depression predicted greater likelihood of smoking for European (p = .009) but not US participants. Europeans were more likely to be abstinent for both outcomes (p < .01). Conclusions: These results extend studies demonstrating varenicline is associated with less withdrawal-related depression, and suggest it aids cessation even in smokers with depressive symptoms. Findings also suggest regional differences in the relationship between depressive symptoms and cessation that may be related to differences in prevalence. Implications: This study indicates varenicline may aid cessation partially by reducing withdrawal-related symptoms of depression. It also suggests that the impact of depressive symptoms on cessation varies regionally, and that this variation may be related to differences in smoking prevalence.
Authors: Ron Borland; Hua-Hie Yong; James Balmford; Jae Cooper; K Michael Cummings; Richard J O'Connor; Ann McNeill; Mark P Zanna; Geoffrey T Fong Journal: Nicotine Tob Res Date: 2010-10 Impact factor: 4.244
Authors: Eric G Devine; Megan E Waters; Megan Putnam; Caitlin Surprise; Katie O'Malley; Courtney Richambault; Rachel L Fishman; Clifford M Knapp; Elissa H Patterson; Ofra Sarid-Segal; Chris Streeter; Laurie Colanari; Domenic A Ciraulo Journal: Clin Trials Date: 2013-07-18 Impact factor: 2.486
Authors: Damaris J Rohsenow; Jennifer W Tidey; Rosemarie A Martin; Suzanne M Colby; Robert M Swift; Lorenzo Leggio; Peter M Monti Journal: Addiction Date: 2017-07-04 Impact factor: 6.526
Authors: Karen Moore; Ron Borland; Hua-Hie Yong; Mohammad Siahpush; K Michael Cummings; James F Thrasher; Geoffrey T Fong Journal: Int J Public Health Date: 2012-06-20 Impact factor: 3.380
Authors: Philip H Smith; Karin A Kasza; Andrew Hyland; Geoffrey T Fong; Ron Borland; Kathleen Brady; Matthew J Carpenter; Karen Hartwell; K Michael Cummings; Sherry A McKee Journal: Nicotine Tob Res Date: 2015-04 Impact factor: 4.244
Authors: Adam M Leventhal; Susan E Ramsey; Richard A Brown; Heather R LaChance; Christopher W Kahler Journal: Nicotine Tob Res Date: 2008-03 Impact factor: 4.244
Authors: Pebbles Fagan; Pallav Pohkrel; Thaddeus Herzog; Ian Pagano; Donna Vallone; Dennis R Trinidad; Kari-Lyn Sakuma; Kymberle Sterling; Craig S Fryer; Eric Moolchan Journal: Drug Alcohol Depend Date: 2015-02-14 Impact factor: 4.852
Authors: Allison J Carroll; Kristine Kim; Andrew Miele; Matthew Olonoff; Frank T Leone; Robert A Schnoll; Brian Hitsman Journal: Addict Behav Date: 2019-04-03 Impact factor: 3.913
Authors: John B Correa; David Lawrence; Benjamin S McKenna; Natassia Gaznick; Phillip A Saccone; Sarah Dubrava; Neal Doran; Robert M Anthenelli Journal: Nicotine Tob Res Date: 2021-08-29 Impact factor: 4.244